請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89620
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊永立 | zh_TW |
dc.contributor.advisor | Yung-Li Yang | en |
dc.contributor.author | 余登揚 | zh_TW |
dc.contributor.author | Teng-Yang Yu | en |
dc.date.accessioned | 2023-09-13T16:06:15Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-13 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-08-01 | - |
dc.identifier.citation | 1. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric blood & cancer 2007;48(2):124-31. DOI: 10.1002/pbc.21039.
2. Jordan MB, Allen CE, Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatric blood & cancer 2019;66(11):e27929. DOI: 10.1002/pbc.27929. 3. Ammann S, Lehmberg K, Zur Stadt U, et al. Effective immunological guidance of genetic analyses including exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis. J Clin Immunol 2017;37(8):770-780. DOI: 10.1007/s10875-017-0443-1. 4. Cetica V, Sieni E, Pende D, et al. Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. J Allergy Clin Immunol 2016;137(1):188-196.e4. (In eng). DOI: 10.1016/j.jaci.2015.06.048. 5. Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood 2018;132(1):89-100. (In eng). DOI: 10.1182/blood-2017-11-814244. 6. Bode SF, Ammann S, Al-Herz W, et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica 2015;100(7):978-88. (In eng). DOI: 10.3324/haematol.2014.121608. 7. Rigante D, Emmi G, Fastiggi M, Silvestri E, Cantarini L. Macrophage activation syndrome in the course of monogenic autoinflammatory disorders. Clin Rheumatol 2015;34(8):1333-9. DOI: 10.1007/s10067-015-2923-0. 8. Lee WI, Chen SH, Hung IJ, et al. Clinical aspects, immunologic assessment, and genetic analysis in Taiwanese children with hemophagocytic lymphohistiocytosis. Pediatr Infect Dis J 2009;28(1):30-4. DOI: 10.1097/INF.0b013e3181813592. 9. Chen X, Wang F, Zhang Y, et al. Genetic variant spectrum in 265 Chinese patients with hemophagocytic lymphohistiocytosis: Molecular analyses of PRF1, UNC13D, STX11, STXBP2, SH2D1A, and XIAP. Clin Genet 2018;94(2):200-212. (In eng). DOI: 10.1111/cge.13363. 10. Koh KN, Im HJ, Chung NG, et al. Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party. Eur J Haematol 2015;94(1):51-9. (In eng). DOI: 10.1111/ejh.12399. 11. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic acids research 2010;38(16):e164. (In eng). DOI: 10.1093/nar/gkq603. 12. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine 2015;17(5):405-423. DOI: 10.1038/gim.2015.30. 13. Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Briefings in bioinformatics 2013;14(2):178-92. (In eng). DOI: 10.1093/bib/bbs017. 14. Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics 2019;35(11):1978-1980. (In eng). DOI: 10.1093/bioinformatics/bty897. 15. Liao CH, Lee NC, Jou ST, Chiang BL, Yu HH. UNC13D mutation presenting as fulminant familial hemophagocytic lymphohistiocytosis. J Microbiol Immunol Infect 2020;53(6):1039-1041. DOI: 10.1016/j.jmii.2020.04.001. 16. Renaux A, Papadimitriou S, Versbraegen N, et al. ORVAL: a novel platform for the prediction and exploration of disease-causing oligogenic variant combinations. Nucleic acids research 2019;47(W1):W93-W98. DOI: 10.1093/nar/gkz437. 17. Versbraegen N, Gravel B, Nachtegael C, et al. Faster and more accurate pathogenic combination predictions with VarCoPP2.0. BMC Bioinformatics 2023;24(1):179. DOI: 10.1186/s12859-023-05291-3. 18. Versbraegen N, Fouché A, Nachtegael C, et al. Using game theory and decision decomposition to effectively discern and characterise bi-locus diseases. Artif Intell Med 2019;99:101690. (In eng). DOI: 10.1016/j.artmed.2019.06.006. 19. Ballew BJ, Yeager M, Jacobs K, et al. Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita. Human Genetics 2013;132(4):473-480. DOI: 10.1007/s00439-013-1265-8. 20. Ballew BJ, Joseph V, De S, et al. A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome. PLoS Genetics 2013;9(8):e1003695. DOI: 10.1371/journal.pgen.1003695. 21. Moon WY, Powis SJ. Does natural killer cell deficiency (NKD) increase the risk of cancer? NKD may increase the risk of some virus induced cancer. Front Immunol 2019;10:1703. (In eng). DOI: 10.3389/fimmu.2019.01703. 22. Keskitalo S, Haapaniemi EM, Glumoff V, et al. Dominant TOM1 mutation associated with combined immunodeficiency and autoimmune disease. npj Genomic Medicine 2019;4(1). DOI: 10.1038/s41525-019-0088-5. 23. Saettini F, Herriot R, Prada E, et al. Prevalence of immunological defects in a cohort of 97 Rubinstein–Taybi syndrome patients. Journal of Clinical Immunology 2020;40(6):851-860. DOI: 10.1007/s10875-020-00808-4. 24. Suspitsin EN, Guseva MN, Kostik MM, et al. Next generation sequencing analysis of consecutive Russian patients with clinical suspicion of inborn errors of immunity. Clin Genet 2020;98(3):231-239. DOI: 10.1111/cge.13789. 25. Yagi H, Furutani Y, Hamada H, et al. Role of TBX1 in human del22q11.2 syndrome. Lancet (London, England) 2003;362(9393):1366-73. DOI: 10.1016/s0140-6736(03)14632-6. 26. Elkaim E, Neven B, Bruneau J, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study. Journal of Allergy and Clinical Immunology 2016;138(1):210-218.e9. DOI: 10.1016/j.jaci.2016.03.022. 27. An WB, Liu C, Wan Y, Chang LX, Chen XY, Zhu XF. Clinical features and gene mutations of children with Shwachman-Diamond syndrome and malignant myeloid transformation. Zhongguo Dang Dai Er Ke Za Zhi 2020;22(5):460-465. (In chi). DOI: 10.7499/j.issn.1008-8830.2001133. 28. Kawakami T, Mitsui T, Kanai M, et al. Genetic analysis of Shwachman-Diamond syndrome: Phenotypic heterogeneity in patients carrying identical SBDS mutations. The Tohoku Journal of Experimental Medicine 2005;206(3):253-259. DOI: 10.1620/tjem.206.253. 29. Schaballie H, Renard M, Vermylen C, et al. Misdiagnosis as asphyxiating thoracic dystrophy and CMV-associated haemophagocytic lymphohistiocytosis in Shwachman-Diamond syndrome. European Journal of Pediatrics 2013;172(5):613-622. DOI: 10.1007/s00431-012-1908-0. 30. Dror Y, Ginzberg H, Dalal I, et al. Immune function in patients with Shwachman-Diamond syndrome. Br J Haematol 2001;114(3):712-7. (In eng). DOI: 10.1046/j.1365-2141.2001.02996.x. 31. Tesi B, Davidsson J, Voss M, et al. Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood 2017;129(16):2266-2279. (In eng). DOI: 10.1182/blood-2016-10-743302. 32. Ahmed IA, Farooqi MS, Vander Lugt MT, et al. Outcomes of hematopoietic cell transplantation in patients with germline SAMD9/SAMD9L mutations. Biol Blood Marrow Transplant 2019;25(11):2186-2196. DOI: 10.1016/j.bbmt.2019.07.007. 33. Oliveira JB, Bidère N, Niemela JE, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proceedings of the National Academy of Sciences 2007;104(21):8953-8958. DOI: 10.1073/pnas.0702975104. 34. Niemela JE, Lu L, Fleisher TA, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 2011;117(10):2883-6. (In eng). DOI: 10.1182/blood-2010-07-295501. 35. Yilmaz E, Kuehn HS, Odakir E, et al. Common variable immunodeficiency, autoimmune hemolytic anemia, and pancytopenia associated with a defect in IKAROS. Journal of pediatric hematology/oncology 2021;43(3):e351-e357. (In eng). DOI: 10.1097/mph.0000000000001976. 36. Salzer U, Chapel HM, Webster AD, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005;37(8):820-8. DOI: 10.1038/ng1600. 37. Tsujita Y, Mitsui-Sekinaka K, Imai K, et al. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome–like immunodeficiency. Journal of Allergy and Clinical Immunology 2016;138(6):1672-1680.e10. DOI: 10.1016/j.jaci.2016.03.055. 38. Neves JF, Doffinger R, Barcena-Morales G, et al. Novel PLCG2 Mutation in a Patient With APLAID and Cutis Laxa. Front Immunol 2018;9:2863. DOI: 10.3389/fimmu.2018.02863. 39. Bogaert DJ, Dullaers M, Kuehn HS, et al. Early-onset primary antibody deficiency resembling common variable immunodeficiency challenges the diagnosis of Wiedeman-Steiner and Roifman syndromes. Scientific Reports 2017;7(1). DOI: 10.1038/s41598-017-02434-4. 40. Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW. FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance. Biochim Biophys Acta 2014;1839(11):1316-22. (In eng). DOI: 10.1016/j.bbagrm.2014.09.016. 41. Serwas NK, Huemer J, Dieckmann R, et al. CEBPE-mutant specific granule deficiency correlates with aberrant granule organization and substantial proteome alterations in neutrophils. Front Immunol 2018;9:588. DOI: 10.3389/fimmu.2018.00588. 42. Jorgensen SE, Christiansen M, Ryo LB, et al. Defective RNA sensing by RIG-I in severe influenza virus infection. Clin Exp Immunol 2018;192(3):366-376. DOI: 10.1111/cei.13120. 43. Booth DR, Gillmore JD, Lachmann HJ, et al. The genetic basis of autosomal dominant familial Mediterranean fever. QJM 2000;93(4):217-21. DOI: 10.1093/qjmed/93.4.217. 44. Rossi-Semerano L, Hermeziu B, Fabre M, Koné-Paut I. Macrophage activation syndrome revealing familial Mediterranean fever. Arthritis Care & Research 2011;63(5):780-783. DOI: 10.1002/acr.20418. 45. Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol 2015;39:115-23. (In eng). DOI: 10.1016/j.semcdb.2015.01.015. 46. Shen M, Tang L, Shi X, Zeng X, Yao Q. NLRP12 autoinflammatory disease: a Chinese case series and literature review. Clinical Rheumatology 2017;36(7):1661-1667. DOI: 10.1007/s10067-016-3410-y. 47. Günther C, Berndt N, Wolf C, Lee-Kirsch MA. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3′ repair exonuclease 1 (TREX1). JAMA Dermatology 2015;151(4):426. DOI: 10.1001/jamadermatol.2014.3438. 48. Bin Khathlan Y, Almutairi S, Albadr FB, Alangari AA, Alsultan A. Case report: Durable response to ruxolitinib in a child with TREX1-related disorder. Front Pediatr 2023;11:1178919. DOI: 10.3389/fped.2023.1178919. 49. Goldfarb Y, Givony T, Kadouri N, et al. Mechanistic dissection of dominant AIRE mutations in mouse models reveals AIRE autoregulation. Journal of Experimental Medicine 2021;218(11). DOI: 10.1084/jem.20201076. 50. Constantine GM, Lionakis MS. Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunological Reviews 2019;287(1):103-120. DOI: 10.1111/imr.12714. 51. Ueda N, Ida H, Washio M, et al. Clinical and genetic features of patients with TNFRSF1A variants in Japan: Findings of a nationwide survey. Arthritis & Rheumatology 2016;68(11):2760-2771. DOI: 10.1002/art.39793. 52. Horneff G, Rhouma A, Weber C, Lohse P. Macrophage activation syndrome as the initial manifestation of tumour necrosis factor receptor 1-associated periodic syndrome (TRAPS). Clin Exp Rheumatol 2013;31(3 Suppl 77):99-102. (In eng). 53. Lu HY, Biggs CM, Blanchard-Rohner G, Fung S-Y, Sharma M, Turvey SE. Germline CBM-opathies: From immunodeficiency to atopy. Journal of Allergy and Clinical Immunology 2019;143(5):1661-1673. DOI: 10.1016/j.jaci.2019.03.009. 54. Mustelin T, Bottini N, Stanford SM. The contribution of PTPN22 to rheumatic disease. Arthritis & Rheumatology 2019;71(4):486-495. DOI: 10.1002/art.40790. 55. Kozycki CT, Kodati S, Huryn L, et al. Gain-of-function mutations in ALPK1 cause an NF-kappaB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome. Ann Rheum Dis 2022;81(10):1453-1464. DOI: 10.1136/annrheumdis-2022-222629. 56. Lepelley A, Della Mina E, Van Nieuwenhove E, et al. Enhanced cGAS-STING–dependent interferon signaling associated with mutations in ATAD3A. Journal of Experimental Medicine 2021;218(10). DOI: 10.1084/jem.20201560. 57. Garshasbi M, Mahmoudi M, Razmara E, et al. Identification of RELN variant p.(Ser2486Gly) in an Iranian family with ankylosing spondylitis; the first association of RELN and AS. European Journal of Human Genetics 2020;28(6):754-762. DOI: 10.1038/s41431-020-0573-4. 58. Lou YJ, Jin J, Mai WY. Ankylosing spondylitis presenting with macrophage activation syndrome. Clin Rheumatol 2007;26(11):1929-30. DOI: 10.1007/s10067-007-0538-9. 59. Ren Y, Xiao F, Cheng F, et al. Whole exome sequencing reveals a novel LRBA mutation and clonal hematopoiesis in a common variable immunodeficiency patient presented with hemophagocytic lymphohistiocytosis. Exp Hematol Oncol 2021;10(1):38. DOI: 10.1186/s40164-021-00229-y. 60. Kuijpers TW, Baars PA, aan de Kerk DJ, et al. Common variable immunodeficiency and hemophagocytic features associated with a FAS gene mutation. J Allergy Clin Immunol 2011;127(6):1411-4 e2. DOI: 10.1016/j.jaci.2011.01.046. 61. Canna SW, Marsh RA. Pediatric hemophagocytic lymphohistiocytosis. Blood 2020;135(16):1332-1343. (In eng). DOI: 10.1182/blood.2019000936. 62. Schulert GS, Cron RQ. The genetics of macrophage activation syndrome. Genes Immun 2020;21(3):169-181. DOI: 10.1038/s41435-020-0098-4. 63. Steen EA, Hermiston ML, Nichols KE, Meyer LK. Digenic inheritance: evidence and gaps in hemophagocytic lymphohistiocytosis. Front Immunol 2021;12:777851. DOI: 10.3389/fimmu.2021.777851. 64. Jin Z, Wang Y, Wang J, et al. Primary hemophagocytic lymphohistiocytosis in adults: the utility of family surveys in a single-center study from China. Orphanet Journal of Rare Diseases 2018;13(1). DOI: 10.1186/s13023-017-0753-7. 65. Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 2017;130(25):2728-2738. DOI: 10.1182/blood-2017-06-788349. 66. Rabbani B, Tekin M, Mahdieh N. The promise of whole-exome sequencing in medical genetics. Journal of Human Genetics 2014;59(1):5-15. DOI: 10.1038/jhg.2013.114. 67. Shaw P, Shizuru J, Hoenig M, Veys P. Conditioning perspectives for primary immunodeficiency stem cell transplants. Front Pediatr 2019;7:434. (In eng). DOI: 10.3389/fped.2019.00434. 68. Seo JJ. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies. Blood Res 2015;50(3):131-9. (In eng). DOI: 10.5045/br.2015.50.3.131. 69. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016;75(4):644-51. (In eng). DOI: 10.1136/annrheumdis-2015-208690. 70. ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74(9):1636-44. (In eng). DOI: 10.1136/annrheumdis-2015-207546. 71. McDermott H, Sherlaw-Sturrock C, Baptista J, Hartles-Spencer L, Naik S. Rapid exome sequencing in critically ill children impacts acute and long-term management of patients and their families: A retrospective regional evaluation. Eur J Med Genet 2022;65(9):104571. DOI: 10.1016/j.ejmg.2022.104571. 72. Morrone K, Wang Y, Huizing M, et al. Two novel mutations identified in an African-American child with Chediak-Higashi syndrome. Case Reports in Medicine 2010;2010:1-4. DOI: 10.1155/2010/967535. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89620 | - |
dc.description.abstract | 論述重點
本研究目的為使用全外顯子定序,分析台灣兒童嗜血症候群相關基因變異之分布情形、與臨床表現及預後之關係。嗜血症候群是一類罕見的症候群,症狀以發燒、全血球低下、多重器官衰竭為主,進展通常十分快速,若無法早期診斷加以即時的治療,常危及生命。雖然嗜血症候群病患的表現類似,但其成因複雜且非單一機轉可以概括。先前已有許多研究發表可在符合HLH-2004診斷標準的兒童嗜血症候群病患檢測出潛在性致病之基因變異。另一研究將全外顯子定序整合到嗜血症候群的診斷流程中,指出此檢測方式可在許多先前已接受針對家族性嗜血症候群基因群定序篩檢後無特殊發現的病患中,發現其他的致病機轉;當中包含一些可受惠於特定治療方案如造血幹細胞移植或標靶治療的疾病,如可造成先天性免疫缺乏及自體發炎的單基因疾病。由此可見全外顯子定序檢測有其附加價值。 方法 本研究的收案對象為臨床診斷為嗜血症候群之兒童,包含符合HLH-2004診斷標準的病患,以及部分符合此標準但合併血球吞噬現象的病患。取得符合收案標準之研究對象的周邊血或骨髓檢體後,進一步提取檢體中的基因體DNA進行全外顯子定序分析。初步得到之基因變異,做篩選利用的標準包括:虛擬基因檢測組套、最小等位基因頻率、表型共分離現象、電腦模擬預測、免疫細胞表達程度、與已知疾病相關性、蛋白功能和孟德爾遺傳模式等。經篩選所得之基因變異根據ACMG指引進行分類,並將致病性、可能致病性和不確定意義的基因變異列為潛在疾病致因變異。最後透過Integrative Genomics Viewer、Varsome和Sanger測序進行驗證,並將得到的基因型資訊與臨床數據進行相關分析。 結果與討論 本研究共有57位患者參與,收案區間橫跨25年。透過全外顯子定序,可在台灣47%的台灣兒童嗜血症候群病患檢出可能的致病性變異。在本研究中,大多數測得的變異位於與先天性免疫缺陷相關的基因中,其中可導致控制病原體能力受損的基因變異佔30%;可導致自體發炎的基因變異佔17%。只有5%的受試者在與淋巴細胞毒殺功能缺失相關的基因中帶有可能的致病性變異,其中觀察到一個在不同病患身上重複出現、位於UNC13D之內含子的病理性變異。本研究發現最常見的嗜血症候群誘因為感染和自體免疫疾病;被這兩種誘因之其一誘發的患者中,有一半可測得潛在的分子診斷。整體存活率為43%(95%信賴區間:23%〜61%;追蹤時間之中位數:8.4個月)。在不同嗜血症候群基因型類別之間,並未觀察到整體存活率有顯著差異。 結論 台灣兒童嗜血症候群病患的基因頻譜有其獨特性及多樣性,其中可能的致病性基因變異大多位於和先天性免疫缺乏或自體發炎疾病相關的基因中。作為一個能找出嗜血症候群之潛在基因診斷、得以針對特定疾病作出適當處置之工具,全外顯子定序有其適切性;然而其對於預後的影響,仍需前瞻性研究進一步評估。 | zh_TW |
dc.description.abstract | Background
Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome characterized by clinical features such as fever, pancytopenia, and multi-organ failure. The progression of the disease is rapid, and delayed diagnosis and treatment can have fatal consequences. However, the underlying mechanisms of the disease are diverse. Previous studies have indicated that potentially disease-causing variants were identified in a significant proportion of pediatric HLH patients who met the HLH-2004 criteria. One study integrated whole exome sequencing (WES) into the diagnostic process and suggested that additional pathogenic mechanisms may be uncovered in patients who did not have a genetic explanation based on previous targeted sequencing tests for familial HLH genes. Consequently, specific options like hematopoietic stem cell transplantation or targeted therapy could be considered for patients with monogenic primary immunodeficiency and monogenic autoinflammatory disease. This study aims to explore the genetic landscape of Taiwanese pediatric HLH patients through WES, establish genotype-phenotype correlations, and discover novel variants and genes associated with HLH. Methods WES was conducted on pediatric patients diagnosed with HLH, either meeting the HLH-2004 criteria or presenting hemophagocytosis with partially fulfilled criteria. Genomic DNA was extracted from peripheral blood or bone marrow cells for the WES analysis. Variant filtering criteria included the use of a virtual gene panel, minor allele frequency cutoff, phenotype cosegregation, in silico prediction, immune cell expression, relevance to known diseases, protein function, and Mendelian inheritance. Selected variants were classified according to ACMG guidelines, with pathogenic variants, likely pathogenic variants, and variants of uncertain significance reported as potential disease-causing variants. Validation was achieved through Integrative Genomics Viewer, Varsome, and Sanger sequencing. The genetic information was then correlated with clinical data. Results A total of 57 patients were enrolled in this study, spanning a period of 25 years. Through the implementation of WES testing, potential disease-causing variants were detected in 47% of Taiwanese pediatric HLH patients. Within this study, the majority of the identified variants were found in genes associated with inborn errors of immunity, resulting in impaired pathogen control (30%) or autoinflammation (17%). Only 5% of participants had likely disease-causing variants in genes related to impaired lymphocyte cytotoxicity, with the observation of a recurrent intronic UNC13D pathogenic variant. Infections and autoimmune diseases were the most common triggers for HLH, with half of these patients showing an underlying molecular diagnosis. The overall survival (OS) was 43% (95% CI: 23%~61%; median follow-up time: 8.4 months). No significant difference in OS was noted among different HLH genetic profiles. Conclusion The genetic landscape of HLH phenotype in pediatric patients in Taiwan is diverse, with the majority of potential disease-causing variants identified in genes associated with primary immunodeficiency and autoinflammatory diseases. Notably, only a few variants related to impaired lymphocyte cytotoxicity were identified. This distinct distribution of variants compared to other studies with cohorts of different ethnicities suggests the effect of population stratification. WES proved to be a viable diagnostic approach for uncovering underlying genetic causes of HLH syndrome, enabling disease-specific management strategies. Prospective trials are needed to evaluate the impact of WES on prognosis. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-13T16:06:15Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-13T16:06:15Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 誌謝.......................................................................................................................………i
中文摘要……………………………………………………………………………......ii 英文摘要…………………………………………………………………………….....iv 第一章 正文 1.1 Introduction…………………………………………………………..…….....P.1 1.2 Methods…………………………………………………………………….....P.4 1.3 Results………………………………………………………………………...P.7 1.4 Discussion……………………………………………………...……………P.13 第二章 圖表 2.1 Figures……………………………………………………………………….P.20 Figure 1. Workflow of the study…………………………..…...…………………..…...P.20 Figure 2. Genetic profile for all the participants with clinical HLH diagnosis………….P.21 Figure 3. Genetic profile for participants with HLH-2004 criteria fit…………………..P.22 Figure 4. Genetic profile for participants with partially fit HLH-2004 criteria…………P.22 Figure 5. Genetic profiles from another multiethnic HLH cohort………………………P.23 Figure 6. HLH-associated triggers by HLH genetic profile…………………………….P.24 Figure 7. HLH-associated trigger by age at diagnosis…………………………………..P.25 Figure 8. HLH genetic profile by age at diagnosis……………………………………...P.26 Figure 9. Maximum level of therapy received by HLH genetic profile…………………P.27 Figure 10. Overall survival of HLH participants……………………………………….P.28 Figure 11. Kaplan-Meier survival curve by HLH genetic profile……………………….P.29 Figure 12. Kaplan-Meier survival curve by HLH-associated triggers…………………..P.30 2.2 Tables………………………………………………………………………..P.31 Table 1. Demographic data of participants…………………………………………..…P.31 Table 2. Potential disease-causing variants by gene category…………………………..P.33 Table 3. Rare and potential amino acid-changing variant pairs for digenic analysis in familial HLH genes…………………………………………………………………….P.37 Table 4. Genetic findings and Kaplan-Meier survival estimates...……………………...P.39 Table 5. HLH-associated trigger and Kaplan-Meier survival estimates………………...P.39 參考文獻…………………………………………………………………………….P.40 | - |
dc.language.iso | en | - |
dc.title | 以次世代定序檢測兒童嗜血症候群病患之基因變異 | zh_TW |
dc.title | Detecting Genetic Variations in Pediatric Hemophagocytic Lymphohistiocytosis Patients Using Next Generation Sequencing | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.coadvisor | 陳璿宇 | zh_TW |
dc.contributor.coadvisor | Hsuan-Yu Chen | en |
dc.contributor.oralexamcommittee | 江伯倫;李妮鍾 | zh_TW |
dc.contributor.oralexamcommittee | Bor-Luen Chiang;Ni-Chung Lee | en |
dc.subject.keyword | 嗜血症候群,全外顯子定序,先天性免疫缺陷,原發性免疫缺乏,自體發炎疾病, | zh_TW |
dc.subject.keyword | hemophagocytic lymphohistiocytosis,whole-exome sequencing,inborn errors of immunity,primary immunodeficiency,autoinflammatory disease, | en |
dc.relation.page | 49 | - |
dc.identifier.doi | 10.6342/NTU202302359 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-08-02 | - |
dc.contributor.author-college | 醫學院 | - |
dc.contributor.author-dept | 臨床醫學研究所 | - |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 1.96 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。